Fitch K, Pelizzari PM, Pyenson B. Cost drivers of cancer care: a retrospective analysis of Medicare and commercially insured population claim data 2004-2014. Milliman (commissioned by the Community Oncology Alliance). April 2016. https://www.milliman.com/-/media/milliman/importedfiles/uploadedfiles/insight/2016/trends-in-cancer-care.ashx. Accessed 24 Mar 2023.

Shankaran V, Unger JM, Darke AK, et al. S1417CD: a prospective multicenter cooperative group-led study of financial hardship in metastatic colorectal cancer patients. J Natl Cancer Inst. 2022;114(3):372–80. https://doi.org/10.1093/jnci/djab210.

Article  PubMed  PubMed Central  Google Scholar 

Leighl NB, Nirmalakumar S, Ezeife DA, et al. An arm and a leg: the rising cost of cancer drugs and impact on access. Am Soc Clin Oncol Educ Book. 2021;41:1–12. https://doi.org/10.1200/EDBK_100028.

Article  PubMed  Google Scholar 

Abrams HR, Durbin S, Huang CX, et al. Financial toxicity in cancer care: origins, impact, and solutions. Transl Behav Med. 2021;11(11):2043–54. https://doi.org/10.1093/tbm/ibab091.

Article  PubMed  Google Scholar 

Al-Ziftawi NH, Shafie AA, Mohamed Ibrahim MI. Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):655–66. https://doi.org/10.1080/14737167.2020.1794826. (Epub 2020 Jul 27).

Article  PubMed  Google Scholar 

U.S. Food & Drug Administration. Biosimilars action plan: balancing innovation and competition. July 2018. https://www.fda.gov/media/114574/download. Accessed 24 Mar 2023.

U.S. Food & Drug Administration. Biosimilars. Updated December 13, 2022. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars. Accessed 24 Mar 2023.

Chopra R, Lopes G. Improving access to cancer treatments: the role of biosimilars. J Glob Oncol. 2017;3(5):596–610. https://doi.org/10.1200/JGO.2016.008607.

Article  PubMed  PubMed Central  Google Scholar 

Godman B, Hill A, Simoens S, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):527–40. https://doi.org/10.1080/14737167.2021.1884546. (Epub 2021 Mar 11).

Article  PubMed  Google Scholar 

Calleja MA, Albanell J, Aranda E, et al. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain. Eur J Hosp Pharm. 2023;30(e1):e40–7. https://doi.org/10.1136/ejhpharm-2021-002955. (Epub 2021 Nov 22).

Article  PubMed  Google Scholar 

Socal M, Ballreich J, Chyr L, Anderson G. Biosimilar medications – savings opportunities for large employers: a report for the ERISA Industry Committee (ERIC). March 2020. https://www.eric.org/wp-content/uploads/2020/03/JHU-Savings-Opportunities-for-Large-Employers.pdf. Accessed 24 Mar 2023.

Association for Accessible Medicines. 2022 U.S. generic and biosimilar medicines savings report. September 2022. https://accessiblemeds.org/resources/reports/2022-savings-report. Accessed 24 Mar 2023.

IQVIA Institute for Human Data Science. Biosimilars in the United States 2023-2027: competition, savings, and sustainability. January 31, 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-2027. Accessed 24 Mar 2023.

FDA approves first biosimilar for the treatment of cancer [press announcement]. Silver Spring, MD: U.S. Food and Drug Administration. September 14, 2017. https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-cancer. Accessed 24 Mar 2023.

Amgen and Allergan’s MvasiTM (bevacizumab-awwb) and KanjintiTM (trastuzumab-anns) now available in the United States [news release]. Thousand Oaks, CA: Amgen. July 18, 2019. https://www.amgen.com/media/news-releases/2019/07/amgen-and-allergans-mvasi-bevacizumabawwb-and-kanjinti-trastuzumabanns-now-available-in-the-united-states/. Accessed 24 Mar 2023.

Thatcher N, Goldschmidt JH, Thomas M, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res. 2019;25(7):2088–95. https://doi.org/10.1158/1078-0432.CCR-18-2702.

Article  CAS  PubMed  Google Scholar 

Goldschmidt J, Hanes V. The totality of evidence and use of ABP 215, a biosimilar to bevacizumab. Oncol Ther. 2021;9(1):213–23. https://doi.org/10.1007/s40487-020-00133-1.

Article  PubMed  Google Scholar 

Jin R, Mahtani RL, Accortt N, et al. Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US. Ther Adv Med Oncol. 2021;1:13. https://doi.org/10.1177/17588359211041961.

Article  CAS  Google Scholar 

Xiao X, Zhang G, Sun B, et al. Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis. Transl Cancer Res. 2022;11(6):1472–82. https://doi.org/10.21037/tcr-22-71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang L, Lui M, Cao X, et al. Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis. Ther Adv Med Oncol. 2022;20(14):17588359221130500. https://doi.org/10.1177/17588359221130501.

Article  CAS  Google Scholar 

Xu X, Zang S, Xu T, Zhan M, Chen C, Zhang C. Efficacy and safety of bevacizumab biosimilars compared with reference biologics in advanced non-small cell lung cancer or metastatic colorectal cancer patients: a network meta-analysis. Front Pharmacol. 2022;13:880090. https://doi.org/10.3389/fphar.2022.880090. (eCollection 2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verschraegen C, Andric Z, Moiseenko F, et al. Candidate bevacizumab biosimilar CT-P16 versus European Union reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer: a randomized controlled trial. BioDrugs. 2022;36(6):749–60. https://doi.org/10.1007/s40259-022-00552-8. (Epub 2022 Sep 28).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nahleh Z, Lyman GH, Schilsky RL, et al. Use of biosimilar medications in oncology. JCO Oncol Pract. 2022;18(3):177–86. https://doi.org/10.1200/OP.21.00771.

Article  PubMed  Google Scholar 

U.S. Department of Health and Human Services, Office of Inspector General. Medicare Part D and beneficiaries could realize significant spending reductions with increased biosimilar use. March 2022. https://oig.hhs.gov/oei/reports/OEI-05-20-00480.pdf. Accessed 24 Mar 2023.

Chen Z, Wang Y, Yang J, Zhou H, Li G. Real-world use of IBI305, a bevacizumab biosimilar, in a tertiary cancer-specialized hospital in China. J Clin Pharm Ther. 2022;47(12):2274–8. https://doi.org/10.1111/jcpt.13809.

Article  CAS  PubMed  Google Scholar 

Advani S, Biswas G, Sinha S, et al. A prospective, randomized, multiple-dose, multi-center, comparative clinical study to evaluate the efficacy, safety, immunogenicity of a biosimilar bevacizumab (test product, Hetero) and reference medicinal product (bevacizumab, Roche), in patients of metastatic colorectal cancer. J Assoc Physicians India. 2018;66(6):55–9.

PubMed  Google Scholar 

Apsangikar PD, Chaudhry SR, Naik MM, Deoghare SB, Joseph J. Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. Indian J Cancer. 2017;54(3):535–8. https://doi.org/10.4103/ijc.IJC_394_17.

Article  PubMed  Google Scholar 

Booth JP, Pilz J. Retrospective indication-matched cohort study of reference product and biosimilar: bevacizumab versus bevacizumab-awwb. Hosp Pharm. 2022;57(4):455–61. https://doi.org/10.1177/00185787211046865.

Article  CAS  PubMed  Google Scholar 

Jin R, Ogbomo AS, Accortt NA, et al. Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb). Ther Adv Med Oncol. 2023;15:17588359231182386. https://doi.org/10.1177/17588359231182386.

Article  PubMed  PubMed Central  Google Scholar 

Rhodes W, DeClue RW, Accortt NA, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol. 2021;17(36):5119–27. https://doi.org/10.2217/fon-2021-0588.

Article  CAS  PubMed  Google Scholar 

Yang J, Kelton JM, Thompson J, et al. Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice. Am J Manag Care. 2022;28(4):160–6. https://doi.org/10.37765/ajmc.2022.88831.

Article  PubMed  Google Scholar 

Kaiser Permanente. Who we are: fast facts. Updated December 31, 2022. https://about.kaiserpermanente.org/who-we-are/fast-facts. Accessed 24 Mar 2023.

Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9. https://doi.org/10.1097/01.mlr.0000182534.19832.83.

Article  PubMed  Google Scholar 

Carroll NM, Delate T, Menter A, et al. Use of bevacizumab in community settings: toxicity profile and risk of hospitalization in patients with advanced non-small-cell lung cancer. J Oncol Pract. 2015;11(5):356–62. https://doi.org/10.1200/JOP.2014.002980.

Article  PubMed  PubMed Central  Google Scholar 

Botrel TEA, Clark LGO, Paladini LE. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16(1):677. https://doi.org/10.1186/s12885-016-2734-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Awsare S, Barrueta A, Gutierrez A, et al. The case for letting biosimilars compete. Health Affairs Blog. 2019. https://doi.org/10.1377/hblog20191212.286621.

Article  Google Scholar 

Kaiser Permanente Institute for Health Policy. Biosimilars at Kaiser Permanente. December 2020. https://www.kpihp.org/wp-content/uploads/2020/12/Biosimilars_at_KP_121420_FINAL.pdf. Accessed 24 Mar 2023.

Mehr S. How did Kaiser Permanente reach 95%+ utilization of biosimilar Herceptin and Avastin so quickly? November 7, 2019. https://biosimilarsrr.com/2019/11/07/how-did-kaiser-permanente-reach-95-utilization-of-biosimilar-herceptin-and-avastin-so-quickly/. Accessed 24 Mar 2023.

Bharati B, Klocke S, Ekinci E, et al. Switching from biologic to biosimilar products: insight from an integrated health care system. BioDrugs. 2022;36(1):1–11. https://doi.org/10.1007/s40259-021-00510-w.

Article  Google Scholar 

IQVIA Institute for Human Data Science. Biosimilars in the United States 2020-2024: competition, savings, and sustainability. September 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024.Accessed 24 Mar 2023.

Amgen Biosimilars. 2021 Biosimilar trends report. September 22, 2021. https://www.amgenbiosimilars.com/media/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/USA-CBU-80962_Amgen-2021-Biosimilar-Trends-Report.pdf. Accessed 24 Mar 2023.

Leonard E, Wascovich M, Oskouei S, et al. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102–12. https://doi.org/10.18553/jmcp.2019.25.1.102.

Article  PubMed  Google Scholar 

Kolbe AR, Kearsley A, Merchant L, et al. Physician understanding and willingness to prescribe biosimilars: findings from a US national survey. BioDrugs. 2021;35(3):363–72. https://doi.org/10.1007/s40259-021-00479-6.

Article  PubMed